0000950170-24-012996.txt : 20240208
0000950170-24-012996.hdr.sgml : 20240208
20240208210842
ACCESSION NUMBER: 0000950170-24-012996
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240206
FILED AS OF DATE: 20240208
DATE AS OF CHANGE: 20240208
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Beckman Daniella
CENTRAL INDEX KEY: 0001513422
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39485
FILM NUMBER: 24610902
MAIL ADDRESS:
STREET 1: C/O IDENIX PHARMACEUTICALS, INC.
STREET 2: ONE KENDALL SQUARE, BLDG. 1400
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tango Therapeutics, Inc.
CENTRAL INDEX KEY: 0001819133
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 201 BROOKLINE AVENUE
STREET 2: SUITE 901
CITY: BOSTON
STATE: MA
ZIP: 02215
BUSINESS PHONE: (857) 320-4900
MAIL ADDRESS:
STREET 1: 201 BROOKLINE AVENUE
STREET 2: SUITE 901
CITY: BOSTON
STATE: MA
ZIP: 02215
FORMER COMPANY:
FORMER CONFORMED NAME: BCTG Acquisition Corp.
DATE OF NAME CHANGE: 20200723
4
1
ownership.xml
4
X0508
4
2024-02-06
0001819133
Tango Therapeutics, Inc.
TNGX
0001513422
Beckman Daniella
C/O TANGO THERAPEUTICS, INC.,
201 BROOKLINE AVE., SUITE 901
BOSTON
MA
02215
false
true
false
false
Chief Financial Officer
false
Common Stock
2024-02-06
4
S
false
1908
12.5626
D
134214
D
Common Stock
2024-02-07
4
S
false
1817
12.6198
D
132397
D
The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
Represents the weighted average sales price per share. The shares sold at prices ranging from $12.22 to $12.83 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Represents the weighted average sales price per share. The shares sold at prices ranging from $12.43 to $12.77 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
/s/ Douglas Barry, attorney-in-fact
2024-02-08